Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Heinemann, V, Bosse, D, Jehn, U, Kähny, B, Wachholz, K, Debus, A, Scholz, P, Kolb, H J, Wilmanns, W
Formato: Artigo
Lenguaje:Inglês
Publicado: 1997
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC163899/
https://ncbi.nlm.nih.gov/pubmed/9174183
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares